A single‐centre study evaluating a geriatric screening tool in oncology phase I trial patients
Cancer Reports · 2024
DOI: 10.1002/cnr2.2083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2024. Verfasst von Mary Van Zyl und 10 weiteren Autor:innen. Beteiligte Einrichtung: Drug Development Unit, Royal Marsden Hospital/Institute of Cancer Research, Sutton, UK. Hauptthemen laut MEDLINE: Geriatric Assessment, Neoplasms, Clinical Trials, Phase I as Topic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, National Institute for Health and Care Research.
Abstract (Originalsprache)
Background
Though cancer is more prevalent in the older population, this patient group are underrepresented in phase I oncology trials.
Aims
We evaluated the use of a geriatric screening tool (SAOP3) in patients of 70 years of age or older who attended a Phase I Clinical Trials Unit, with the aim of assessing the feasibility of the tool and identifying potential unmet needs in this patient group.
Methods
Twenty‐two patients over the age of 70 completed the SAOP3 questionnaire. Geriatric impairments and needs were analysed with descriptive statistics. Qualitative responses were grouped in themes using structured thematic analysis.
Results
All of patients triggered at least 1 geriatric domain, most commonly mobility. Six core themes were identified as being important to the patient including family, friends and positivity. On cognition assessment over 20% of patients triggered as requiring further cognitive assessment. The group had a relatively high screen fail risk.
Conclusion
In conclusion, routine geriatric screening withSAOP3 was feasible and identified areas of patient need. Results highlight the prevalence of psychological distress and cognitive impairment. Geriatric screening offers an opportunity for prehabilitation prior to trial and support during trial participation to optimise safety and improve trial access.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Drug Development Unit, Royal Marsden Hospital/Institute of Cancer Research, Sutton, UK.
- Senior Adult Oncology Programme, Royal Marsden Hospital, Sutton, UK.
- Breast Unit & Senior Adult Oncology Programme, Royal Marsden Hospital, Sutton, UK.
ORCID-Profile: Mary Van Zyl, Nicolo Matteo Luca Battisti
Förderung
- National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research
- National Institute for Health and Care Research
Zitieren
APA
Van Zyl, M., Barell, A., Cooley, B., Hanwell, J., Parlak, J., Banerji, U., De Bono, J., Sharp, A., Lopez, J., Battisti, N. M. L., & Minchom, A. (2024). A single‐centre study evaluating a geriatric screening tool in oncology phase I trial patients. Cancer Reports. https://doi.org/10.1002/cnr2.2083
Vancouver
Van Zyl M, Barell A, Cooley B, Hanwell J, Parlak J, Banerji U, et al. A single‐centre study evaluating a geriatric screening tool in oncology phase I trial patients. Cancer Reports. 2024. doi:10.1002/cnr2.2083
BibTeX
@article{VanZyl2024,
author = {Van Zyl, Mary and Barell, Anne and Cooley, Bridget and Hanwell, Janet and Parlak, Josie and Banerji, Udai and De Bono, Johann and Sharp, Adam and Lopez, Juanita and Battisti, Nicolo Matteo Luca and Minchom, Anna},
title = {A single‐centre study evaluating a geriatric screening tool in oncology phase I trial patients},
journal = {Cancer Reports},
year = {2024},
doi = {10.1002/cnr2.2083}
}
EUVIMED